In this article
Maybe the cost is adding up. Maybe you have reached your goal, or the side effects are wearing on you. Whatever the reason, it is fair to ask what happens if you stop.
The good news is that researchers have studied this directly. Three large trials took people off the medicine on purpose and kept measuring. The less welcome news is that, in all three, much of the weight came back.
What happens in your body when you stop
Semaglutide does not leave your body the day you stop. Its half-life is about 1 week, and the label says it stays in your circulation for about 5 to 7 weeks after the last dose [4]. So any change tends to be gradual.
While you take it, semaglutide reduces appetite and calorie intake [4]. When it wears off, that effect goes too. The trials below show what that meant for weight and health markers.
STEP 1 extension: one year after stopping
STEP 1 gave adults with obesity or overweight, without diabetes, either semaglutide 2.4 mg weekly or placebo for 68 weeks, alongside a lifestyle program [1]. At week 68, both the medicine and the lifestyle program stopped [1]. Researchers then followed 327 of the participants for another year [1].
By week 68, the semaglutide group had lost 17.3% of their body weight on average [1]. Over the year after stopping, they regained 11.6 percentage points of it [1]. That left them 5.6% below their starting weight at week 120. The placebo group ended about where they started [1].
Health markers followed the weight. Improvements seen during treatment in things like blood pressure and long-term blood sugar (HbA1c) moved back toward their starting levels for most measures [1]. The authors concluded that the findings confirm obesity is a chronic condition and suggest ongoing treatment is needed to keep the improvements [1].
One limit to keep in mind: the lifestyle program stopped at the same time as the drug [1]. This trial cannot tell us what happens if you keep up exercise and eating changes after stopping.
STEP 4: continuing versus switching to placebo
STEP 4 asked a cleaner question. All 902 participants took semaglutide for 20 weeks, building up to 2.4 mg [2]. Then 803 people who reached that dose were randomly split. Two-thirds kept taking semaglutide and one-third were switched to placebo, for 48 more weeks, and both groups kept a lifestyle program [2]. Most participants (79%) were women, and the average age was 46 [2].
During the first 20 weeks, people lost 10.6% of their weight on average [2]. Over the next 48 weeks, the group that stayed on semaglutide lost another 7.9%. The group switched to placebo gained 6.9% [2]. Waist size, blood pressure and physical functioning scores also came out better in the group that continued [2].
SURMOUNT-4: the same pattern with tirzepatide
Tirzepatide was tested the same way. In SURMOUNT-4, 783 adults took tirzepatide for 36 weeks at the highest dose they could tolerate, 10 mg or 15 mg [3]. The 670 who completed that phase had lost 20.9% of their weight on average [3]. They were then randomly split to keep taking tirzepatide or switch to placebo for 52 weeks [3]. Most (71%) were women [3].
Over that year, the group that stayed on tirzepatide lost another 5.5%. The group switched to placebo regained 14.0% [3]. The difference also shows up in who held on to their progress:
- Kept 80% or more ~89.5%
- Kept less ~10.5%
- Kept 80% or more ~16.6%
- Kept less ~83.4%
89.5% of people who stayed on tirzepatide kept at least 80% of their earlier weight loss at week 88, compared with 16.6% of people switched to placebo [3].
From the very start of the trial to week 88, the tirzepatide group was down 25.3% overall and the placebo group 9.9% [3]. So people who stopped did not, on average, return all the way to where they began within that year. But most of them lost much of their progress.
| Trial | Medicine | After stopping | Change in weight |
|---|---|---|---|
| STEP 1 extension [1] | Semaglutide 2.4 mg | 1 year off the drug and the lifestyle program | Regained 11.6 points of a 17.3% loss |
| STEP 4 [2] | Semaglutide 2.4 mg | 48 weeks on placebo | Gained 6.9%, vs lost 7.9% for those who continued |
| SURMOUNT-4 [3] | Tirzepatide 10 or 15 mg | 52 weeks on placebo | Gained 14.0%, vs lost 5.5% for those who continued |
Why these drugs are treated as long-term
The FDA-approved semaglutide label describes its use as to reduce excess body weight and maintain weight reduction long term, together with diet and physical activity [4]. The withdrawal trials are part of why. When the medicine stops, the appetite effect stops too, and for many people the weight follows.
A 2026 systematic review pulled together 18 reports on what happens after people stop GLP-1 and GIP/GLP-1 medicines [5]. It found that weight regain is common after stopping, but how much varies by drug, study design, follow-up and what treatment comes next [5]. Real-world studies showed smaller and more variable regain than the trials, partly because many people restarted or switched medicines [5].
The review's conclusion is a practical one: stopping should be planned as part of long-term care, with monitoring and shared decisions, rather than treated as the end of a short course [5].
If you are thinking about stopping
There may be good reasons to stop or pause. Pregnancy is one: the label says to stop semaglutide at least 2 months before a planned pregnancy [4]. Side effects, cost, or reaching a goal are others. Whatever the reason, a few things are worth knowing.
- Talk to your clinician first. They can help you plan the timing, decide what to watch, and agree on what to do if weight starts to come back.
- Keep moving, especially strength work. The 2026 review found that the best evidence for a maintenance strategy so far supports supervised exercise. In one trial, people who exercised alongside an older GLP-1 kept off more weight a year after both ended than those who took the drug alone [5]. Evidence for specific diets, tapering or other strategies is still limited [5].
- Do not restart at your old dose on your own. If you miss 2 or more weekly doses, the label says to restart at a lower dose to reduce digestive side effects [4]. Ask your clinician before starting again.
- Watch more than the scale. Since blood pressure and blood sugar improvements can fade after stopping [1], keep up with your usual checkups.
Muscle is part of this too. Our article on muscle loss on semaglutide and tirzepatide covers why strength training matters during and after treatment.
WarriorBabe Health offers semaglutide injections, a semaglutide tablet and tirzepatide injections, prescribed and monitored by licensed clinicians. Ours are compounded by a licensed pharmacy and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness or quality before they are sold [6]. The trial results above come from the FDA-approved products.
Day to dayWhat to do day to day, from the WarriorBabe Show:What happens when you stop taking a GLP-1? →Frequently asked questions
Will I gain the weight back if I stop semaglutide?
Many people regain much of it. In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide and its lifestyle program [1]. Results vary from person to person [5].
How long does semaglutide stay in your system after you stop?
Its half-life is about 1 week, and the label says it stays in your circulation for about 5 to 7 weeks after the last dose [4].
Can I stop semaglutide cold turkey?
The trials stopped it all at once [1, 2]. But how to stop, and whether to, is a decision to make with your clinician, who can plan the timing and what to watch afterward [5].
Does tirzepatide work the same way when you stop?
In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% of their body weight over a year, while those who continued lost another 5.5% [3].
Does exercise stop weight regain after a GLP-1?
It may help, but the evidence is still thin. A 2026 review found one randomized trial supporting supervised exercise after stopping an older GLP-1, and little evidence for other strategies [5].
References
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. pubmed.ncbi.nlm.nih.gov/35441470/
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. pubmed.ncbi.nlm.nih.gov/33755728/
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. pubmed.ncbi.nlm.nih.gov/38078870/
- Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information. DailyMed, US National Library of Medicine. Revised 6/2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Marchetti M, Campisano G, Paragliola RM, et al. Weight regain after discontinuation of GLP-1 and GIP/GLP-1 receptor agonists: a systematic review. Metabolites. 2026;16(10):757. pubmed.ncbi.nlm.nih.gov/42941232/
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
This article is for general information. It is not medical advice and does not replace a visit with a licensed clinician who knows your history. Do not start, stop or change a medication without talking to your clinician. If you think you are having a medical emergency, call 911.
